Macrocyclic peptidomimetics: potential for drug development
McGeary, R.P.; Fairlie, D.P.
Current Opinion in Drug Discovery and Development 1(2): 208-217
1998
ISSN/ISBN: 1367-6733 PMID: 19649821 Document Number: 490695
Document emailed within 1 workday
Related Documents
Johnson, A.P. 2007: Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic Current Opinion in Investigational Drugs 8(2): 168-173Craik, D.J.; Cemazar, M.; Daly, N.L. 2006: The cyclotides and related macrocyclic peptides as scaffolds in drug design Current Opinion in Drug Discovery and Development 9(2): 251-260
Fabio, S. di; Cianfriglia, M.; Flego, M.; Ascione, A.; Gellini, M.; Zamboni, S.; Binelli, A.; Carlini, F.; Germinario, E.; Vella, S. 2006: Animal HU-SCID model of vaginal transmission of HIV-1 for the preclinical evaluation of microbicides. Development of peptidomimetics and mini-antibodies as a new class of microbicides of biotechnological origin Rapporti ISTISAN Istituto Superiore di Sanita (06/50): 298-301
Takano, A.; Miyamoto, Y.; Kawakami, N.; Matsumoto, T. 2016: The potential of e-Health for treatment and prevention for drug dependence process of development and revision of web-based relapse prevention program "e-SMARPP" Nihon Arukoru Yakubutsu Igakkai Zasshi 51(6): 382-392
Whitehouse, P.J.; Sciulli, C.G.; Mason, R.M. 1997: Dementia drug development: use of information systems to harmonize global drug development Psychopharmacology Bulletin 33(1): 129-133
Kigen, G.; Kimaiyo, S.; Nyandiko, W.; Faragher, B.; Sang, E.; Jakait, B.; Owen, A.; Back, D.; Gibbons, S.; Seden, K.; Khoo, S.H.; Nyandiko, W.; Wools-Kaloustian, K.; Kimaiyo, S.; Braitstein, P.; Sang, E.; Jakait, B.; Pastakia, S. 2011: Prevalence of potential drug-drug interactions involving antiretroviral drugs in a large Kenyan cohort Plos one 6(2): E16800
Kantor, R.; Katzenstein, D. 2003: Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution Aids Reviews 5(1): 25-35
Bittner, B.; Mountfield, R.J. 2002: Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters Current Opinion in Drug Discovery and Development 5(1): 59-71
Kelloff, G.J.; Crowell, J.A.; Boone, C.W.; Steele, V.E.; Lubet, R.A.; Greenwald, P.; Alberts, D.S.; Covey, J.M.; Doody, L.A.; Knapp, G.G. 1994: Strategy and planning for chemopreventive drug development: clinical development plans. Chemoprevention Branch and Agent Development Committee. National Cancer Institute Journal of Cellular Biochemistry. Supplement 20: 55-62
Claeson, G. 1994: Synthetic peptides and peptidomimetics as substrates and inhibitors of thrombin and other proteases in the blood coagulation system Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 5(3): 411-436
Sarnecka-Keller, M. 1973: Macrocyclic antibiotics as ionophores of monovalent cations Postepy Biochemii 19(4): 559-576
Zaĭchenko, O.M. 2008: Biosynthesis of macrocyclic trichothecenes: some aspects of physiology Mikrobiolohichnyi Zhurnal 70(2-3): 116-121
Chen, Y.-l.; Yuan, D.; Xu, X.; Fu, H.-z. 2008: Studies on macrocyclic jatrophane diterpenes of Euphorbia kansui Zhongguo Zhong Yao Za Zhi 33(15): 1836-1839
Muller, S.; Guichard, G.; Benkirane, N.; Brown, F.; Van Regenmortel, M.H.; Briand, J.P. 1995: Enhanced immunogenicity and cross-reactivity of retro-inverso peptidomimetics of the major antigenic site of foot-and-mouth disease virus Peptide Research 8(3): 138-144
Alhenc-Gelas, Fçois.; Parmentier, L.; Bisagni, A. 2003: Pharmacogenetic and pharmacogenomic studies. Impact on drug discovery and drug development Therapie 58(3): 275-282
Kutter, E.; Austel, V. 1981: Application of the theory of sets to drug design. Development of a new cardiotonic drug AR-L 115 BS Arzneimittel-Forschung 31(1a): 135-141
Thomas, J.W. 1995: AHi perspectives: flexible drug labeling and its impact on the drug development process. Liability issues Journal of the American Veterinary Medical Association 207(7): 899-900; Discussion: 902-904
Wirken, L.; van Middendorp, H.ët.; Hooghof, C.W.; Sanders, J.S.; Dam, R.E.; van der Pant, K.A.M.I.; Berendsen, E.C.M.; Wellink, H.; Dackus, H.J.A.; Hoitsma, A.J.; Hilbrands, L.B.; Evers, A.W.M. 2017: Pre-donation cognitions of potential living organ donors: the development of the Donation Cognition Instrument in potential kidney donors Nephrology Dialysis Transplantation: Official Publication of the European Dialysis and Transplant Association - European Renal Association 32(3): 573-580
Jantová, S.; Duracková, Z.; Novotný, L.; Urbancíková, M.; Dovinová, I.; Labuda, J.; Wsolová, L. 1998: Macrocyclic Cu(II)tetraanhydroaminobenzaldehyde complex--antiproliferative activity in vitro and in vivo Neoplasma 45(4): 254-260
Donner, E. 1986: Family planning and rural development in Thailand. Operations of the Population and Community Development Association in Thailand and their potential for application elsewhere Schriftenreihe der GTZ, Deutsche Gesellschaft fur Technische Zusammenarbeit, German Federal Re ic 184: 255